Alcaraz's 10¢ Odds Overreach: No Matches in 4 Months, Tenosynovitis Grip, Cincinnati Withdrawal Yesterday

TL;DR

Alcaraz sits at YES 10¢ to defend his US Open title, despite not playing a competitive match since April 2026.
He withdrew from Cincinnati on Aug 5 — the last meaningful tuneup before Flushing Meadows opens Aug 30 — due to tenosynovitis in his right wrist.
Wrist injuries are uniquely resistant to compensation strategies; the careers of Del Potro and Thiem stand as cautionary precedents.
The market prices him at 10% — which may still be generous given the match-fitness deficit, though his pedigree and youth keep the YES from being purely symbolic.

Carlos Alcaraz is the defending US Open champion, world No. 2, and 23 years old with seven Grand Slam titles. He is also a man who has not struck a ball in competition since the Barcelona Open in April. The market has priced that tension at YES 10¢ as of Aug 6. Whether that number is about right, slightly generous, or quietly absurd depends entirely on how seriously one takes a wrist injury that has already claimed better-prepared players than Alcaraz.

What the Market Says

At YES 10¢ and NO 90¢ — captured 2026-08-06 10:01 UTC — the market is essentially saying there is a nine-in-ten chance Alcaraz does not lift the trophy at Flushing Meadows on September 13. The 24-hour volume sits at $48,589, which is healthy for a single-player outright at this stage of the calendar but not so deep that the price cannot be moved by new information.

A 10¢ YES on a reigning Grand Slam champion who is seeded No. 2 in the world is, on its face, a striking number. For context, the typical pre-tournament favorite at a Grand Slam — Jannik Sinner, say, at his peak draw — trades somewhere between 25¢ and 35¢. The market has shaved roughly two-thirds off Alcaraz's baseline probability before a single ball has been struck. That is a substantial discount, and the question is whether it is sufficient.

The argument that it is not sufficient starts with two simple words: match fitness.

The Case

Alcaraz has not played a competitive match in approximately four months. He withdrew from the French Open a full month before the tournament started, pulled out of Wimbledon nearly six weeks before the grass season's marquee event, and on Aug 5 — yesterday — confirmed his absence from the Cincinnati Open, the ATP Masters 1000 event that serves as the sport's last major dress rehearsal before the US Open. Tournament director Bob Moran's statement was diplomatic: "We know Carlos is doing everything he can to get back to playing tournaments as soon as possible." The subtext writes itself.

The injury in question is tenosynovitis — fluid accumulation in the sheath that protects a key tendon in the right wrist. This is not a pulled hamstring or a stiff back that responds to load management and rest. Wrist injuries occupy a distinct and grimmer category in tennis medicine, for a reason that is almost mechanical in its simplicity: there is almost no muscle in the wrist. When a player strains a knee or a calf, physical therapy can build surrounding musculature to absorb and redistribute force. The wrist offers no such workaround. The tendon heals, or it doesn't, and until it does, generating the kind of heavy topspin that defines Alcaraz's game is not merely uncomfortable — it is structurally inadvisable.

The sport has seen this movie before, and the endings have not all been happy. Juan Martin Del Potro, at various points ranked as high as No. 3 in the world and a former US Open champion in his own right, spent the better part of a decade fighting wrist injuries before effectively losing the battle. Dominic Thiem, a Grand Slam champion and former world No. 1, saw a wrist injury strip what should have been his prime years and from which he never fully recovered competitive relevance. Alcaraz is younger than either was at the time of their worst setbacks, and his team has been admirably cautious — he said himself at the Laureus Awards in April, speaking in Spanish, "I have a very long career ahead of me, with many years still to come. Forcing things at this Roland Garros could really harm me for future tournaments." That is a reasonable and mature posture. It is also, almost by definition, incompatible with arriving at a Grand Slam in peak competitive condition.

There is one data point on the optimistic side of the ledger: Alcaraz posted training videos in mid-July showing full-intensity hitting, the first indication since April that the wrist is tolerating load. He was also sporting a new braided hairstyle, which is medically irrelevant but at least confirms he remains in good spirits. His team has not confirmed entry into the Winston-Salem Open (Aug 23 – Sep 1), which would be the final opportunity to accumulate competitive matches before the US Open main draw begins Aug 30. If he skips Winston-Salem, he will walk onto the hardcourts at Flushing Meadows having played zero matches in roughly five months.

That is not an insurmountable deficit for a player of his talent. It is, however, a historically unusual one. Grand Slam titles tend to go to players who arrive healthy, match-hardened, and moving well. Alcaraz, at present, is one of those three things.

The 10¢ price reflects all of this. Whether it reflects it accurately is a harder question. If he enters and plays Winston-Salem and wins two rounds, YES could move sharply. If he skips it entirely, NO at 90¢ looks like a fairly priced consensus, not a mispriced edge. The market is essentially in a holding pattern, waiting on news that has not arrived.

Risks

The honest case for YES is not trivial. Start with the obvious: Alcaraz is 23 years old and has won seven Grand Slams. He won this title in 2025 by beating Jannik Sinner in the final, and Sinner is still the man he would likely need to beat again. At 23, recovery timelines are compressed relative to older players; the same injury that ended Del Potro's competitive prime might be a six-month inconvenience for someone two decades younger.

There is also the question of what "competing" actually requires. A player of Alcaraz's caliber does not need a full block of clay-court warmup tournaments to be dangerous at a hardcourt Grand Slam. His groundstrokes are among the most destructive in the sport when healthy. If the wrist is genuinely improving — and the July training videos suggest it is, cautiously — he could arrive at Flushing Meadows with less match rust than one might fear from the calendar alone.

His team's conservatism is also worth reading charitably. They are not managing a player on the decline; they are protecting a generational asset. Missing Cincinnati, missing Paris, missing Wimbledon — all of it speaks to a medical staff that knows exactly what they have and has no interest in gambling with it for the sake of a ranking point or two. The flip side of that caution is that when Alcaraz does return, the wrist will be genuinely ready, not merely functional.

Sinner, meanwhile, is the prohibitive favorite to repeat, but Sinner has his own history of mid-season disruptions. The draw matters enormously. And hardcourts suit Alcaraz's game as well as any surface. A YES bet at 10¢ is not a bet that Alcaraz is healthy and ready — it is a bet on a low-probability but non-trivial scenario: that he enters, the draw breaks kindly, and the wrist holds for seven matches in two weeks. Stranger things have happened at Flushing Meadows.

The more pointed risk to the NO side is simply that 10¢ is already a low floor. If the news breaks tonight that Alcaraz has withdrawn entirely from the US Open, NO moves toward 99¢ and the position closes near par. The asymmetry for YES buyers is substantial, but so is the probability of walking into that news cold.

For now, the market is pricing a title defense by a player who hasn't played competitive tennis since April, is nursing an injury class with a documented record of persistence, and skipped the sport's best pre-Slam tuneup as of yesterday. That sounds like a market that has the direction right. Whether 10¢ is precisely right — or whether 6¢ or 8¢ would be more defensible — depends on how the next three weeks of silence, or news, unfold.

Winston-Salem entries close shortly. That is the next real data point.

Prices captured at press time and are not live. Not financial advice.